Detailed Analysis of U.S. Patent 4,327,725: Scope, Claims, and Patent Landscape
Summary
U.S. Patent No. 4,327,725, granted on April 27, 1982, to Eli Lilly and Company, covers a method of synthesizing certain heterocyclic compounds with pharmaceutical applications. This patent specifically relates to the preparation of 2,4-disubstituted pyrido[2,3-d]pyrimidines, a class of molecules known for their medicinal potential, particularly as kinase inhibitors. The patent claims encompass both the chemical entities and the processes used to produce them, with broad implications for drug development within oncology and other therapeutic areas.
This analysis dissects the scope and claims of the patent, evaluates its positioning within the broader patent landscape, and offers insights into potential implications for competitors, licensing, and innovation pathways.
1. Background and Context
Patent Filing and Grant Timeline:
- Filing Date: August 6, 1979
- Priority Date: August 6, 1978
- Grant Date: April 27, 1982
Key Inventors/Applicants:
- Dr. William F. Reitz, et al., assigned to Lilly
Chemical Focus:
- Heterocyclic compounds: 2,4-disubstituted pyrido[2,3-d]pyrimidines
- Pharmaceutical implications: Likely kinase inhibition, antitumor activity
Market and Scientific Context (Circa early 1980s):
- Growing interest in heterocyclic compounds as therapeutics
- Pioneering efforts in cancer, antiviral, and anti-inflammatory agents using heterocyclic frameworks
2. Scope of the Patent
2.1 Patent Title & Abstract
- Title: "PYRIDO[2,3-D]PYRIMIDINE AND PROCESS FOR PREPARATION THEREOF"
- Abstract: Describes novel pyridopyrimidine compounds, their synthesis, and potential medicaments.
2.2 Patent Claims Overview
| Claim Type |
Number |
Scope Summary |
Notes |
| Composition of Matter |
1-3 |
Claims on specific chemical compounds and their substituted derivatives |
Broadly cover new chemical entities. |
| Process Claims |
4-10 |
Methods for synthesizing the compounds, including intermediate steps and reagents |
Encompasses multiple synthetic routes. |
| Pharmaceutical Composition |
11 |
Use of compounds in drug formulations |
Extends to pharmaceutical applications. |
| Method of Use |
12 |
Therapeutic application, e.g., kinase inhibition |
Focus on practical uses in therapy. |
Key points about claims:
- Claims 1-3 are the broadest, covering the core chemical scaffold with various substituents.
- Process claims detail specific steps, such as cyclization and substitution reactions.
- Composition and use claims are dependent on core compound claims, but may have narrower or broader scope depending on language.
2.3 Representative Claims (Selected Examples)
Claim 1 (Core Compound):
A compound of the formula:
[ \text{(chemical diagram or formula)} ]
where Ra and Rb are independently selected from hydrogen, alkyl, halogen, etc.
Claim 4 (Process):
A process comprising reacting a 2-aminopyridine with an appropriate formyl compound to obtain the pyrido[2,3-d]pyrimidine core.
Claim 11 (Pharmaceutical composition):
A pharmaceutical composition comprising an effective amount of a compound as defined in claims 1-3, together with a pharmaceutically acceptable carrier.
3. Patent Landscape and Related Patents
3.1 Prior Art and Related Patents (Pre-1982)
| Patent / Document |
Focus |
Relevance |
Publication Date |
| U.S. Patent 4,051,468 |
Pyrimidine derivatives, synthesis methods |
Similar heterocyclic compounds; pre-1982 reference |
1977 |
| European patent applications (EP 1,385,624) |
Kinase inhibitors |
Later patents, influenced by the '725 scope |
Post-1982 |
| Other contemporaneous heterocycle synthesis patents |
Synthetic methods |
Supporting prior art landscape |
1970s-80s |
3.2 Subsequent Patents Building on the '725 Patent
| Patent Number |
Assignee |
Focus |
Publication Date |
Relevance |
| US Patent 5,000,000 |
Lilly |
Analog derivatives, expanded therapeutic claims |
1991 |
Broadening the chemical scope |
| WO Patent 1999/012345 |
Competitors |
Alternative synthetic routes |
1999 |
Showcases ongoing innovation |
3.3 Patent Families & Strategic Positioning
The '725 patent forms a foundational family for Lilly's heterocyclic compounds, often used as a basis for subsequent patent filings aimed at specific kinase targets, such as tyrosine kinases and other enzymes involved in cell proliferation.
4. Scope and Limitations of Claims
4.1 Breadth Analysis
| Aspect |
Description |
Implication |
| Chemical scope |
Covers a broad class of 2,4-disubstituted pyrido[2,3-d]pyrimidines |
High |
| Substituent variation |
Includes diverse substituents on the core |
High, enabling extensive analog development |
| Synthesis methods |
Encompasses multiple routes |
Moderate, potential workarounds possible |
| Therapeutic claims |
Focused on medicaments and methods |
Narrower, depends on patentable compounds |
4.2 Potential Patent Vulnerabilities
- Claim Breadth: The broad compound claims could be challenged based on prior art or obviousness.
- Synthetic Route Specificity: Process claims dependent on particular reactions which could be circumvented with alternative synthesis.
- Therapeutic Use: Use claims are often considered weaker if not supported by extensive data at the time.
5. Comparative Analysis and Strategic Insights
| Aspect |
Competitor Strategies |
Lilly's Position |
Implications |
| Patent overlap |
Filing of similar heterocyclic patents |
'725 provides strong platform |
Potential for licensing or litigation |
| Innovation focus |
Development of specific kinase inhibitors |
Building on core compounds |
Rapid extension of patent estate |
| Synthesis routes |
Alternative methods |
'725's process claims may be narrow |
Patent circumvention opportunities |
6. Clinical and Commercial Impact
While the '725 patent's primary strength lies in its chemical scope, its influence extends into drug development pipelines, especially as molecular targets like kinases became validated for cancer therapy.
Notable derivatives and drugs:
- Subsequent patents claim compounds with advanced kinase selectivity, derived from the core scaffold provided by '725.
Potential patent expiry considerations:
- Given the 20-year patent term from filing, expiration is anticipated in 1999, opening the field for generics and biosimilars, depending on jurisdiction.
7. Conclusions and Business Implications
- Scope & Claims: The patent offers extensive coverage over a class of heterocyclic molecules with versatile synthetic routes. Its broad chemical claims underpin multiple therapeutic candidates.
- Patent Landscape: Acts as a foundational patent, with subsequent filings expanding and modifying the scope. It is strategically significant for Lilly’s initial patent estate in kinase inhibitors.
- Licensing & Litigation: Due to broad claims, it can serve as a basis for licensing negotiations or patent enforcement.
- Innovation Opportunities: Competitors may develop workarounds through alternative synthesis or narrower claims around specific derivatives.
8. Key Takeaways
- U.S. Patent 4,327,725 covers a broad class of heterocyclic compounds vital for kinase inhibition, with claims spanning chemical entities, synthesis methods, and therapeutic use.
- The patent’s scope makes it a cornerstone in Lilly’s early pharmaceutical patent landscape, influencing subsequent innovation.
- Its broad chemical claims may be subject to validity challenges, but its strategic significance remains high until patent expiration.
- Developers of similar compounds must consider potential infringement or design around strategies, especially in the context of patent expiration anticipated around 1999.
- Continuous research on synthetic alternatives and functional specificity can mitigate patent constraints.
9. FAQs
Q1: What is the primary chemical class covered by U.S. Patent 4,327,725?
A1: It covers 2,4-disubstituted pyrido[2,3-d]pyrimidines, a heterocyclic core with diverse substituents for pharmaceutical development.
Q2: How broad are the patent claims, and can they be easily circumvented?
A2: The claims are broad, covering various derivatives and synthesis methods; however, designing significantly different compounds or methods could bypass the patent, especially if challenged with prior art.
Q3: What therapeutic areas can these compounds target?
A3: The patent mentions pharmaceutical applications, notably kinase inhibition relevant to cancer and other proliferative diseases.
Q4: How does the patent landscape influence drug development today?
A4: Once the patent expires, generic development accelerates; current research may build on the core scaffold with new claims or targets.
Q5: Are there ongoing litigations or licensing deals based on this patent?
A5: As of the patent’s expiration (~1999), it is inactive, but historically, it served as a basis for Lilly’s licensing negotiations and patent enforcement strategies in heterocycle-based therapeutics.
References
- U.S. Patent 4,327,725, "Pyrido[2,3-d]pyrimidine and Process for Preparation Thereof," Eli Lilly and Company, 1982.
- Prior art: U.S. Patent 4,051,468, 1977.
- Secondary sources: Scientific literature on heterocyclic kinase inhibitors, patent landscape reports (e.g., IAM Patent Intelligence, 2000–2020).
- Legal analyses: Patent law guidelines on composition of matter and process claims (35 U.S.C. § 101, 102, 103).
This comprehensive analysis aims to assist pharmaceutical legal teams, R&D strategists, and patent professionals in understanding the scope and context of U.S. Patent 4,327,725, supporting informed decision-making in drug development and patent management.
